CDMOs Using Single-use and IIoT Solutions Will Reduce Costs and Enhance Production Efficiency

Monday, November 12, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

The CDMO market is expected to reach $17.38 billion by 2022, finds Frost & Sullivan

SANTA CLARA, Calif.,

Nov. 12, 2018 /PRNewswire/ -- Numerous pharmaceuticals are turning to biologics contract development and manufacturing organizations (CDMOs) for both clinical- and commercial-stage manufacturing in
order to deal with the growing demand for biologics and biosimilars, the capital-intensive nature of the business, and the complex manufacturing requirements. To optimally tap this demand, Bio-CDMOs are expanding their capacities through strategic acquisitions of small- to mid-sized participants with a specific technology, therapeutic, or service expertise.

"With the growing patent cliffs in branded biologics, biosimilars are set to account for almost 15 percent to 20 percent of the business of Bio-CDMOs, thus presenting considerable opportunities in production and co-development," said Unmesh Lal, Program Manager, Transformational Health. "CDMOs are responding by providing value-added services such as regulatory support and engaging in early lifecycle stage projects."

Frost & Sullivan's recent analysis, Global Biologics Contract Development and Manufacturing Organization (CDMO) Market, Forecast to 2022, provides revenue forecasts for the global Bio-CDMO market as well as a breakdown by type of cell culture (mammalian vs. microbial) and service type (drug substance vs. drug product). Additionally, it presents insights into leading disruptive technology trends such as lyophilization, and process analytical technologies (PAT). This market is expected to grow from $9.28 billion in 2017 to $17.38 billion in 2022, at a compound annual growth rate (CAGR) of 13.4 percent.

For further information on this analysis, please visit: http://frost.ly/2v0.

"Disruptive CDMOs like Wuxi Biologics and Samsung Biologics are investing in single-use technologies whereas technology companies like Dassault Systemes and GE are providing IIoT solutions for key manufacturing processes," noted Lal. "In addition, CDMOs are adopting disruptive business models such as virtual biotech, out-licensing, and risk sharing, which could prove profitable in the long term."

Shifting market paradigms have also created opportunities for CDMOs in:

  • Industrial Internet of Things (IIoT) in Manufacturing: The widespread application of IIoT with IT-based solutions supports the establishment of connected value chains, reduces operational costs, and enhances production efficiency.
  • Designer Cell Lines: The emergence of designer cell lines, such as Chinese hamster ovary (CHO), is expected to propel the cell line development market to ~$10 billion in the short term.
  • Biosimilars Co-Development: Integrated biosimilar-specific business models will find high adoption as most companies transfer focus from biologics to biosimilars.
  • Single-use /Disposable Manufacturing: Recent developments across CAR-T cell therapies have shifted biologics manufacturing toward small-volume, high-value production employing single-use/disposable technologies.
  • Bioanalytical Development and Services: The rising relevance of bioanalytical services in biologic development is encouraging market participants to implement integrated laboratory management systems.

Global Biologics Contract Development and Manufacturing Organization (CDMO) Market, Forecast to 2022 is part of Frost & Sullivan's global Life Sciences Growth Partnership Service program.

About Frost & SullivanFor over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Global Biologics Contract Development and Manufacturing Organization (CDMO) Market, Forecast to 2022MC9B-52

Contact:Mariana FernandezT: +1 210 348 10 12T: +54 11 4778 3540E: Mariana.Fernandez@frost.com

http://ww2.frost.com

 

Cision View original content:http://www.prnewswire.com/news-releases/cdmos-using-single-use-and-iiot-solutions-will-reduce-costs-and-enhance-production-efficiency-300748354.html

SOURCE Frost & Sullivan



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store